Validation of the Birefringent Amblyopia Screener (Retinal Polarization Scanner), the Rebion Blinq.™ [Letter]

David G Hunter Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, 02115, USACorrespondence: David G Hunter Department of OphthalmologyBoston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA 02115, USATel +1 617-35...

Full description

Bibliographic Details
Main Author: Hunter DG
Format: Article
Language:English
Published: Dove Medical Press 2020-09-01
Series:Clinical Ophthalmology
Subjects:
Online Access:https://www.dovepress.com/validation-of-the-birefringent-amblyopia-screener-retinal-polarization-peer-reviewed-article-OPTH
id doaj-4e6361bf894b4d65844e5480bbeb267c
record_format Article
spelling doaj-4e6361bf894b4d65844e5480bbeb267c2020-11-25T02:58:47ZengDove Medical PressClinical Ophthalmology1177-54832020-09-01Volume 142599260056828Validation of the Birefringent Amblyopia Screener (Retinal Polarization Scanner), the Rebion Blinq.™ [Letter]Hunter DGDavid G Hunter Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, 02115, USACorrespondence: David G Hunter Department of OphthalmologyBoston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA 02115, USATel +1 617-355-6766Email david.hunter@childrens.harvard.edu I write to clarify some of the conclusions made by Dr. Arnold in his study of the blinq.™ vision screener.1 The goal of vision screening is early detection of amblyopia and strabismus, which until now, due to limitations in technology, could only be achieved by detecting refractive risk factors. Unfortunately, risk factor screening results in under-detection of patients with strabismus and over referral of children who would not benefit from treatment.2 The blinq. device was not designed to detect refractive risk factors; instead, the device detects amblyopia directly by performing a binocular retinal polarization scan to identify reduced binocularity, microstrabismus, and fixation instability without regard to refractive status.3 In his study, Dr. Arnold evaluated the ability of blinq. to detect amblyopia risk factors, but the performance of  blinq. and all vision screening technology should be evaluated in the context of how well it identifies patients who meet diagnostic criteria for amblyopia and strabismus.4 Out of concern that his study design might create confusion among readers, I contacted Dr. Arnold, who kindly provided his de-identified data to allow me to determine which patients had referral warranted disease, not just risk factors.   View the original paper by Arnoldhttps://www.dovepress.com/validation-of-the-birefringent-amblyopia-screener-retinal-polarization-peer-reviewed-article-OPTHamblyopiaamblyopia risk factorbirefringentretinal polarizationfixation instabilityphotoscreeningstrabismus.
collection DOAJ
language English
format Article
sources DOAJ
author Hunter DG
spellingShingle Hunter DG
Validation of the Birefringent Amblyopia Screener (Retinal Polarization Scanner), the Rebion Blinq.™ [Letter]
Clinical Ophthalmology
amblyopia
amblyopia risk factor
birefringent
retinal polarization
fixation instability
photoscreening
strabismus.
author_facet Hunter DG
author_sort Hunter DG
title Validation of the Birefringent Amblyopia Screener (Retinal Polarization Scanner), the Rebion Blinq.™ [Letter]
title_short Validation of the Birefringent Amblyopia Screener (Retinal Polarization Scanner), the Rebion Blinq.™ [Letter]
title_full Validation of the Birefringent Amblyopia Screener (Retinal Polarization Scanner), the Rebion Blinq.™ [Letter]
title_fullStr Validation of the Birefringent Amblyopia Screener (Retinal Polarization Scanner), the Rebion Blinq.™ [Letter]
title_full_unstemmed Validation of the Birefringent Amblyopia Screener (Retinal Polarization Scanner), the Rebion Blinq.™ [Letter]
title_sort validation of the birefringent amblyopia screener (retinal polarization scanner), the rebion blinq.™ [letter]
publisher Dove Medical Press
series Clinical Ophthalmology
issn 1177-5483
publishDate 2020-09-01
description David G Hunter Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, 02115, USACorrespondence: David G Hunter Department of OphthalmologyBoston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA 02115, USATel +1 617-355-6766Email david.hunter@childrens.harvard.edu I write to clarify some of the conclusions made by Dr. Arnold in his study of the blinq.™ vision screener.1 The goal of vision screening is early detection of amblyopia and strabismus, which until now, due to limitations in technology, could only be achieved by detecting refractive risk factors. Unfortunately, risk factor screening results in under-detection of patients with strabismus and over referral of children who would not benefit from treatment.2 The blinq. device was not designed to detect refractive risk factors; instead, the device detects amblyopia directly by performing a binocular retinal polarization scan to identify reduced binocularity, microstrabismus, and fixation instability without regard to refractive status.3 In his study, Dr. Arnold evaluated the ability of blinq. to detect amblyopia risk factors, but the performance of  blinq. and all vision screening technology should be evaluated in the context of how well it identifies patients who meet diagnostic criteria for amblyopia and strabismus.4 Out of concern that his study design might create confusion among readers, I contacted Dr. Arnold, who kindly provided his de-identified data to allow me to determine which patients had referral warranted disease, not just risk factors.   View the original paper by Arnold
topic amblyopia
amblyopia risk factor
birefringent
retinal polarization
fixation instability
photoscreening
strabismus.
url https://www.dovepress.com/validation-of-the-birefringent-amblyopia-screener-retinal-polarization-peer-reviewed-article-OPTH
work_keys_str_mv AT hunterdg validationofthebirefringentamblyopiascreenerretinalpolarizationscannertherebionblinqtradeletter
_version_ 1724705186091368448